Abstract
Diabetes mellitus is an independent risk factor for the development of coronary artery disease, myocardial infarction, hypertension, and dyslipidemia. The treatment of diabetes has been mainly focused on maintaining normal blood glucose concentrations. Insulin and hypoglycemic agents have been used as standard therapeutic strategies. However, these are characterized by limited efficacy and adverse side effects, making the development of new therapeutic alternatives mandatory. Inhibition of glucose reabsorption in the kidney, mediated by Sodium Glucose Transporters (SGLTs), represents a promising therapeutic approach. The high-affinity sodium glucose cotransporter (SGLT1) is expressed to some extent in the kidney and contributes to glucose reabsorption, However Genetic mutations in the SGLT1 gene leading to a functional defect are responsible for glucose/galactose malabsorption. The low-affinity sodium glucose cotransporter (SGLT2), which is expressed specifically in the kidney, plays a major role in renal glucose reabsorption in the proximal tubule. We focused on SGLT2 as a molecular target for this review because it plays a major role in renal glucose reabsorption, and its tissue distribution is limited in the kidney to reduce the likelihood for mechanism-based side effects. Phlorizin, a natural phenolic O-glucoside has been known to induce glucosuria for more than 100 years. As it is not a specific SGLT inhibitor, later on o-glucoside is replaced by c-glycoside as it is resistant to hydrolysis by β-glucosidases. The present review summarizes the concept of SGLT2 selective target based therapy for diabetes mellitus and the current clinical and preclinical development of SGLT2 inhibitors.
Keywords: Sodium glucose transporters, diabetes mellitus, dyslipidemia, glucotoxicity, glucose facilitated transporters, β-glucosidases, hypoglycemia
Mini-Reviews in Medicinal Chemistry
Title: Exploring Newer Target Sodium Glucose Transporter 2 for the Treatment of Diabetes Mellitus
Volume: 10 Issue: 10
Author(s): H.B. Vaidya and R.K. Goyal
Affiliation:
Keywords: Sodium glucose transporters, diabetes mellitus, dyslipidemia, glucotoxicity, glucose facilitated transporters, β-glucosidases, hypoglycemia
Abstract: Diabetes mellitus is an independent risk factor for the development of coronary artery disease, myocardial infarction, hypertension, and dyslipidemia. The treatment of diabetes has been mainly focused on maintaining normal blood glucose concentrations. Insulin and hypoglycemic agents have been used as standard therapeutic strategies. However, these are characterized by limited efficacy and adverse side effects, making the development of new therapeutic alternatives mandatory. Inhibition of glucose reabsorption in the kidney, mediated by Sodium Glucose Transporters (SGLTs), represents a promising therapeutic approach. The high-affinity sodium glucose cotransporter (SGLT1) is expressed to some extent in the kidney and contributes to glucose reabsorption, However Genetic mutations in the SGLT1 gene leading to a functional defect are responsible for glucose/galactose malabsorption. The low-affinity sodium glucose cotransporter (SGLT2), which is expressed specifically in the kidney, plays a major role in renal glucose reabsorption in the proximal tubule. We focused on SGLT2 as a molecular target for this review because it plays a major role in renal glucose reabsorption, and its tissue distribution is limited in the kidney to reduce the likelihood for mechanism-based side effects. Phlorizin, a natural phenolic O-glucoside has been known to induce glucosuria for more than 100 years. As it is not a specific SGLT inhibitor, later on o-glucoside is replaced by c-glycoside as it is resistant to hydrolysis by β-glucosidases. The present review summarizes the concept of SGLT2 selective target based therapy for diabetes mellitus and the current clinical and preclinical development of SGLT2 inhibitors.
Export Options
About this article
Cite this article as:
Vaidya H.B. and Goyal R.K., Exploring Newer Target Sodium Glucose Transporter 2 for the Treatment of Diabetes Mellitus, Mini-Reviews in Medicinal Chemistry 2010; 10 (10) . https://dx.doi.org/10.2174/138955710792007213
DOI https://dx.doi.org/10.2174/138955710792007213 |
Print ISSN 1389-5575 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5607 |
Call for Papers in Thematic Issues
Bioprospecting of Natural Products as Sources of New Multitarget Therapies
According to the Convention on Biological Diversity, bioprospecting is the exploration of biodiversity and indigenous knowledge to develop commercially valuable products for pharmaceutical and other applications. Bioprospecting involves searching for useful organic compounds in plants, fungi, marine organisms, and microorganisms. Natural products traditionally constituted the primary source of more than ...read more
Computational Frontiers in Medicinal Chemistry
The thematic issue "Computational Frontiers in Medicinal Chemistry" provides a robust platform for delving into state-of-the-art computational methodologies and technologies that significantly propel advancements in medicinal chemistry. This edition seeks to amalgamate top-tier reviews spotlighting the latest trends and breakthroughs in the fusion of computational approaches, including artificial intelligence (AI) ...read more
Natural Products and Dietary Supplements in Alleviation of Metabolic, Cardiovascular, and Neurological Disorders
Metabolic disorders like diabetes, obesity, inflammation, oxidative stress, cancer etc, cardiovascular disorders like angina, myocardial infarction, congestive heart failure etc as well as neurological disorders like Alzheimer?s, Parkinson?s, Epilepsy, Depression, etc are the global burden. They covered the major segment of the diseases and disorders from which the human community ...read more
Natural Products in Drug Discovery
Natural products have always been one of the important ways of drug discovery due to their novel skeleton and diverse functional group characteristics. According to statistics, between 1981 and 2019, the FDA approved a total of 1,394 small molecule drugs for marketing, of which 930 marketed drugs originated from the ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
An Overview on Cardiovascular Protective Effects of Catechins
Cardiovascular & Hematological Disorders-Drug Targets Cardiovascular Effects of Antiretroviral Drugs: Clinical Review
Cardiovascular & Hematological Disorders-Drug Targets Nitric Oxide and its Antithrombotic Action in the Cardiovascular System
Current Drug Targets - Cardiovascular & Hematological Disorders The Relationship between Inflammatory and Oxidative Stress Biomarkers, Atherosclerosis and Rheumatic Diseases
Current Pharmaceutical Design Anti-Inflammatory Drugs and Statins for Arterial Stiffness Reduction
Current Pharmaceutical Design Lipases in Medicine: An Overview
Mini-Reviews in Medicinal Chemistry Mechanism and Development of Modern General Anesthetics
Current Topics in Medicinal Chemistry The Role of Adenosine in Alzheimers Disease
Current Neuropharmacology p66 Shc as the Engine of Vascular Aging
Current Vascular Pharmacology Adrenoceptor Polymorphisms in Hypertension and Diabetes with Obesity- Update in 2013
Current Hypertension Reviews Metabolic and Cardiovascular Complications of Highly Active Antiretroviral Therapy for HIV Infection
Current HIV Research Insulin Resistance as a Proinflammatory State: Mechanisms, Mediators, and Therapeutic Interventions
Current Drug Targets Radionuclide PET and PET/CT in Coronary Artery Disease
Current Pharmaceutical Design Improving of Nutraceutical Features of Many Important Mediterranean Vegetables by Inoculation with a New Commercial Product
Current Pharmaceutical Biotechnology The Valsalva Maneuver and Alzheimers Disease: Is there a link?
Current Alzheimer Research High-Density Lipoprotein and Low-Density Lipoprotein Subfractions in Patients with Chronic Kidney Disease
Current Vascular Pharmacology C-Reactive Protein and Hypertension: Is there A Causal Relationship?
Current Pharmaceutical Design Melanotropins as Drugs for the Treatment of Obesity and Other Feeding Disorders: Potential and Problems
Current Topics in Medicinal Chemistry From Erythropoietin to Its Peptide Derivatives: Smaller but Stronger
Current Protein & Peptide Science The Structural Determinations of the Leucine Zipper Coiled-Coil Domains of the cGMP-Dependent Protein Kinase Iα and Its Interaction with the Myosin Binding Subunit of the Myosin Light Chains Phosphase
Protein & Peptide Letters